Article Information
History
- December 9, 2021.
Article Versions
- You are currently viewing Version 1 of this article (December 9, 2021 - 23:08).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Meghana Kshirsagar1,a,
- Sumit Mukherjeea,
- Md Nasira,
- Nicholas Beckera,
- Juan Lavista Ferresa and
- Barbra A. Richardsonb,c
- aAI for Good Research Lab, Microsoft Corporation, Redmond, WA 98052, USA
- bDepartments of Biostatistics and Global Health, Univ. of Washington, Seattle, WA 98195, USA
- cVaccine and Infectious Disease Division, Fred Hutch Cancer Research Center, Seattle, WA 98109, USA
- ↵1Corresponding author: Meghana Kshirsagar (Meghana.Kshirsagar{at}microsoft.com)., Address: 1 Microsoft Way, Redmond, WA 98052, phone: +1 (425) 421-8258, fax: +1 425-706-7329
Posted December 09, 2021.
Risk of hospitalization and mortality after breakthrough SARS-CoV-2 infection by vaccine type and previous SARS-CoV-2 infection utilizing medical claims data
